

# Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

NCT07332091

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	CSL Behring
<b>Enrollment</b>	84 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Adult (≥ 18 years) and has provided written informed consent.
- Confirmed diagnosis of HFE-HH in medical history.
- Evidence of iron overload as shown by:
  - TSAT > 45% (confirmed at 2 visits, at least 14 days apart) at Screening; and
  - Serum ferritin ≥ 200 nanogram per milliliter (ng/mL) and > 5000 ng/mL (confirmed at 2 visits, at least 14 days apart) at Screening; and
- ... and 2 more (see full listing online)

### Exclusion (1)

- Clinically relevant laboratory abnormalities, 12-lead electrocardiogram (ECG) findings, or medical history.

## Locations (96 total)

---

Banner MD Anderson, Gilbert, Arizona, United States  
Infinity Clinical Trials, San Diego, California, United States  
Medical Oncology Associates of San Diego, San Diego, California, United States  
... and 93 more locations